Investor Ideas, Trading Ideas and Stocks to Watch : #AIEye #Podcast: #AI #Stocks in the News: (OTCPINK: $GTCH) (NYSE: $ACN)

Tuesday, June 13, 2023

#AIEye #Podcast: #AI #Stocks in the News: (OTCPINK: $GTCH) (NYSE: $ACN)

#AIEye #Podcast: #AI #Stocks in the News: (OTCPINK: $GTCH) (NYSE: $ACN)

GBT Announces Magic2 Suite of AI-Driven EDA Software, and Accenture to Invest $3B into Data & AI

Global Generative #AI in #DrugDiscovery Market to Reach $1.12B by 2032

Vancouver, Kelowna, Delta, BC – June 13, 2023 – Investorideas.com, a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye-watching stock news, deal tracker and advancements in artificial intelligence – featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2023/061323-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2023/artificial-intelligence/06131GTCH-ACN.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (OTCPINK:GTCH) (NYSE:ACN)

GBT Technologies Inc. (OTC PINK:GTCH) has posted an update covering its EDA segment intellectual properties (IP) portfolio with the announcement of Magic2, an AI driven electronic design automation (EDA) software Suite helping engineers to speed up time consuming task work during the integrated circuits (IC) design phase. The suite comprises eight integrated software applications covering specific component processes of the IC design cycle. Four of these eight tools (Epsilon, Sigma, Omega, and Phi) have received patent approval. Mansour Khatib, CEO of GBT, explained:

"It sounds technical because it is, but simply spoken, Magic2 is a suite of individual EDA tools which we believe can potentially save 1000's and 1000's hours of engineering time, speeding up the microchip design process and at the same time building better, faster, greener, cheaper, and more reliable microchips. Epsilon has been a double milestone for GBT Technologies Inc. as we already developed a limited working software version V1.0 which has performed in an operational setting and started the whole Magic2 concept. With all the positive industry feedback, GBT will continue to focus on expanding the family of its various EDA patents and concentrating on strategic potential partnerships with the goal of integrating these technologies into a broad marketplace, diversifying the risk within all these areas, and increasing shareholder value of that portfolio.”

Accenture (NYSE:ACN) has announced a $3 billion investment over three years into its Data & AI practice to help clients across all industries rapidly and responsibly advance and use AI to achieve greater growth, efficiency and resilience. Paul Daugherty, group chief executive, Accenture Technology, said:

"Over the next decade, AI will be a mega-trend, transforming industries, companies, and the way we live and work, as generative AI transforms 40% of all working hours. Our expanded Data & AI practice brings together the full power and breadth of Accenture in creating industry-specific solutions that will help our clients harness AI’s full potential to reshape their strategy, technology, and ways of working, driving innovation and value responsibly and faster than ever before."

Global Generative AI in Drug Discovery Market to Reach $1.12B by 2032

A report published by MarketResearch.biz finds that the global market for Generative AI in Drug Discovery is projected to grow from $109 million USD in 2022 to $1.12 billion by 2032, registering a compound annual growth rate (CAGR) of 27.1 percent in the forecast period 2023-32. The following excerpt from the report overview outlines the impact of Generative AI on drug discovery:

Generative AI is a type of machine learning that involves the formation of new data like new molecules, based on patterns learned from existing data. In the context of drug discovery, generative AI algorithms can be trained on large databases of known drug molecules and their properties to create new compounds that are predicted to have therapeutic effects. The generative AI in drug discovery market is driven by the maximizing demand for the most efficient & effective price drug discovery processes.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

About Investorideas.com - Big Investing Ideas

We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water.

The Investorideas.com podcasts are also available on Apple Podcasts , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: GTCH is a paid featured AI stock .More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com